Money
Filter News
Found 84,891 articles
-
The Swiss drugmaker raised its full-year guidance Tuesday projecting net sales to grow in the high-single to low double-digit range while reporting better-than-expected first-quarter results.
-
Follow along as BioSpace keeps you up to date on the latest pharma and biotech M&As, from announcements to closings.
-
Brise Pharmaceuticals Raises nearly $20M in Series Pre-A and Pre-A+ Financing
4/23/2024
Brise Pharmaceuticals Co., LTD., a pioneering company specializing in innovative treatments for acute and chronic pain, has recently completed Pre-A and Pre-A+ financing with a total of approximately $20 million.
-
Nanostics Receives Funding from the University of Alberta Innovation Fund to Propel Adoption of the ClarityDX Prostate Test
4/23/2024
University of Alberta Innovation Fund invests in Nanostics to support adoption of its ClarityDX Prostate test.
-
Danaher Reports First Quarter 2024 Results
4/23/2024
Danaher Corporation announced results for the quarter ended March 29, 2024. All results in this release reflect only continuing operations unless otherwise noted.
-
CN Bio Raises $21 Million USD in First Close of Series B Investment Round
4/23/2024
CN Bio, a leading provider of single- and multi-organ microphysiological systems, announced it has raised a $21 million investment in the first close of its Series B fundraising round.
-
Quest Diagnostics Reports First Quarter 2024 Financial Results; Raises Guidance for Full Year 2024
4/23/2024
Quest Diagnostics Incorporated, a leading provider of diagnostic information services, announced financial results for the first quarter ended March 31, 2024.
-
Red Arrow Therapeutics Inc. closes $4.5M Seed Extension round
4/23/2024
Red Arrow Therapeutics Inc. closed a $4.5M Seed Extension round, raising from four, top-tier institutional investors in Japan.
-
QT Imaging Holdings (Nasdaq: QTI) to Ring The Nasdaq Stock Market Opening Bell
4/22/2024
QT Imaging Holdings, Inc., a medical device company engaged in research, development, and commercialization of innovative body imaging systems, is proud to announce the Opening Bell Ceremony at the Nasdaq MarketSite in Times Square.
-
OraSure to Announce First Quarter 2024 Financial Results and Host Earnings Call on May 8th
4/22/2024
OraSure Technologies, Inc. has scheduled its regular earnings conference call covering first quarter 2024 financial results and certain business developments for 4:45 p.m. ET on Wednesday, May 8, 2024.
-
Catalyst Pharmaceuticals to Report First Quarter 2024 Financial Results on May 8, 2024
4/22/2024
Catalyst Pharmaceuticals, Inc. announced that it will release its first quarter 2024 financial results after the market close on Wednesday, May 8, 2024.
-
Rubedo Life Sciences Closes $40M Series A Financing Led by Khosla Ventures and Ahren Innovation Capital
4/22/2024
Rubedo Life Sciences, a biopharmaceutical company committed to developing first-in-class therapies targeting senescent cells which drive age-related diseases, announced the closing of a $40M Series A financing round.
-
Bristol Myers Squibb and Cellares Announce a $380M Worldwide Capacity Reservation and Supply Agreement for the Manufacture of CAR T Cell Therapies to Bring the Promise of Cell Therapy to More Patients, Faster
4/22/2024
Bristol Myers Squibb and Cellares, the first Integrated Development and Manufacturing Organization dedicated to clinical and industrial-scale cell therapy manufacturing, announced a worldwide capacity reservation and supply agreement for the manufacture of CAR T cell therapies in a transaction valued up to $380M in upfront and milestone payments.
-
Genetic Technologies Announces Closing of US$2 Million Registered Direct Offering
4/22/2024
Genetic Technologies Limited announces the closing of its previously announced registered offering for the purchase and sale of 1,000,000 American Depositary Shares, each representing thirty ordinary shares of the Company, at an offering price of US$2.00 per ADS.
-
Profound Medical to Release First Quarter 2024 Financial Results on May 9 – Conference Call to Follow
4/22/2024
Profound Medical Corp. will announce its first quarter 2024 financial results after market close on Thursday, May 9, 2024.
-
Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares - April 22, 2024
4/22/2024
Biohaven Ltd. announced the closing of its underwritten public offering of 6,451,220 of its common shares, which includes the full exercise of the underwriters' option to purchase 841,463 additional common shares, at a public offering price of $41.00 per share.
-
Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-K
4/22/2024
Exicure, Inc., announced it received a notice of non-compliance from Nasdaq Stock Market LLC on April 17, 2024 notifying the Company that, as a result of the Company’s failure to timely file its Annual Report on Form 10-K for the year ended December 31, 2023, the Company is not in compliance with Nasdaq Listing Rule 5250, which requires listed companies to timely file all periodic financial reports with the U.S.
-
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - April 22, 2024
4/22/2024
Avidity Biosciences, Inc. announced that on April 20, 2024, the Human Capital Management Committee of Avidity's Board of Directors granted non-qualified stock option awards to purchase an aggregate of 37,500 shares of its common stock and 18,750 restricted stock units to three new non-executive employees under the Avidity Biosciences, Inc. 2022 Employment Inducement Incentive Award Plan.
-
Nicox Provides First Quarter 2024 Update and Full Year 2023 Financial Results
4/22/2024
Nicox SA, an international ophthalmology company, provided the revenue and cash position for Nicox SA and its subsidiaries for the first quarter of 2024 and financial results for Nicox SA for the full year of 2023, as approved by the Board of Directors on April 19, 2024, and provided an update on key future milestones.
-
OrthoPediatrics Corp. to Report First Quarter 2024 Financial Results on May 7, 2024
4/22/2024
OrthoPediatrics Corp., a company focused exclusively on advancing the field of pediatric orthopedics, announced that the Company is scheduled to release its first quarter 2024 financial results on Monday, May 6, 2024, after the market closes.